Anti-Human Fractalkine (Clone 51637)

Quality Tested by Leinco Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing CX3CL1. A suggested method would be to stain cells expressing CX3CL1 with 0.25 µg per 1 - 2.5 x 10⁶ cells in a total staining volume of ≤ 200 µl followed by PN:M1189.

Fractalkine

Next Day Ambient

Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4

CyTOF-ready: Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Mouse Anti-Human Fractalkine (FKN) (Clone 51637) recognizes an epitope on Human FKN. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

Purified Recombinant Human FKN (Accession # P78423)